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Oxygen homeostasis represents an organizing principle for understanding metazoan evolution,
development, physiology, and pathobiology. The hypoxia-inducible factors (HIFs) are transcrip-
tional activators that function as master regulators of oxygen homeostasis in all metazoan species.
Rapid progress is being made in elucidating homeostatic roles of HIFs in many physiological
systems, determining pathological consequences of HIF dysregulation in chronic diseases, and
investigating potential targeting of HIFs for therapeutic purposes.Oxygen is central to biology because it is used during respiration.
O2 serves as the final electron acceptor in oxidative phosphory-
lation, which carries with it the risk of generating reactive oxygen
species (ROS). ROS react with cellular macromolecules and
alter their biochemical or physical properties, resulting in cell
dysfunction or death. As a consequence, metazoan organisms
have evolved elaborate cellular metabolic and systemic physio-
logical systems that are designed to maintain oxygen homeo-
stasis. This Review focuses on the role of hypoxia-inducible
factors (HIFs) as master regulators of oxygen homeostasis
and, in particular, on recent advances in understanding their
roles in physiology and medicine. Due to space limitations and
the remarkably pleiotropic effects of HIFs, the description of
such roles will be illustrative rather than comprehensive.
O2 and Evolution, Part 1
O2 started accumulating in Earth’s atmosphere 2.5 billion
years ago. Increased availability of atmospheric O2 led to the
evolution of an extraordinarily efficient system of oxidative
phosphorylation that transfers chemical energy stored in carbon
bonds of organic molecules to the high-energy phosphate bond
in ATP, which is used to power physicochemical reactions in
living cells. Energy produced by mitochondrial respiration is
sufficient to power the development and maintenance of multi-
cellular organisms, which could not be sustained by energy
produced by glycolysis alone (Lane and Martin, 2010). The
dimensions of primitive metazoan species were small enough
that O2 could diffuse from the atmosphere to all of the organ-
ism’s thousand cells, as is the case for the worm Caenorhabditis
elegans. To escape the constraints placed on organismal
growth by diffusion, systems evolved that could conduct air to
cells deep within the body, and these designs were sufficient
for O2 delivery to organisms with hundreds of thousands of
cells, such as the fly Drosophila melanogaster. The final leap
in body scale occurred in vertebrates, and it was associated
with the evolution of complex respiratory, circulatory, and
nervous systems designed to efficiently capture and distributeO2 to hundreds of millions of millions of cells, such as the adult
Homo sapiens.
Hypoxia-Inducible Factors
Hypoxia-inducible factor 1 (HIF-1) is expressed by all extant
metazoan species analyzed to date (Loenarz et al., 2011).
HIF-1 consists of the subunits HIF-1a and HIF-1b. Each subunit
contains basic helix-loop-helix-PAS (bHLH-PAS) domains
(Wang et al., 1995) that mediate heterodimerization and DNA
binding (Jiang et al., 1996a). HIF-1b heterodimerizes with other
bHLH-PAS proteins and is present in excess, such that HIF-1a
protein levels determine HIF-1 transcriptional activity (Semenza
et al., 1996).
Under well-oxygenated conditions, HIF-1a is bound by the
von Hippel-Lindau (VHL) protein. VHL recruits an ubiquitin
ligase that targets HIF-1a for proteasomal degradation (Kaelin
and Ratcliffe, 2008). VHL binding is dependent upon hydroxyl-
ation of a specific proline residue in HIF-1a by the prolyl
hydroxylase PHD2. PHD2 uses O2 as a substrate, and thus,
its activity is inhibited under hypoxic conditions (Epstein
et al., 2001). In the reaction, one oxygen atom is inserted into
the prolyl residue, and the other atom is inserted into the
cosubstrate a-ketoglutarate, splitting it into CO2 and succinate
(Kaelin and Ratcliffe, 2008). Factor-inhibiting HIF-1 (FIH-1)
represses HIF-1a transactivation function (Mahon et al.,
2001). It hydroxylates an asparaginyl residue on HIF-1a, using
O2 and a-ketoglutarate as substrates, thereby blocking the
association of HIF-1a with the p300 coactivator protein (Lando
et al., 2002). Dimethyloxalylglycine (DMOG), which is a compet-
itive antagonist of a-ketoglutarate, inhibits hydroxylases and
induces HIF-1-dependent transcription (Epstein et al., 2001).
HIF-1 activity is also induced by iron chelators (e.g., desferriox-
amine) and cobalt chloride, which inhibit hydroxylases by dis-
placing Fe(II) from the catalytic center (Epstein et al., 2001).
Studies in cultured cells (Jiang et al., 1996b) and isolated,
perfused, and ventilated lung preparations (Yu et al., 1998)
revealed an exponential increase in HIF-1a levels at O2Cell 148, February 3, 2012 ª2012 Elsevier Inc. 399
Figure 1. Regulation of Glucose Metabolism
Under hypoxic conditions, hypoxia-inducible factor 1 (HIF-1) activates the
transcription of genes encoding the following: glucose transporters and
glycolytic enzymes, which increase the flux of glucose to pyruvate;
PDK1 (pyruvate dehydrogenase kinase), which inactivates PDH (pyruvate
dehydrogenase), the mitochondrial enzyme that converts pyruvate to acetyl
CoA for entry into the tricarboxylic acid (TCA/citric acid/Krebs) cycle; LDHA
(lactate dehydrogenase), which converts pyruvate to lactate; and the mito-
chondrial proteins BNIP3 and BNIP3L, which induce mitochondrial-selective
autophagy. The shunting of substrate away from the mitochondria reduces
ATP production but prevents excess ROS production that occurs due to
inefficient electron transport under hypoxic conditions.concentrations <6% (40 mm Hg), which cannot be explained
by known biochemical properties of the hydroxylases. In most
adult tissues, O2 concentrations are in the range of 3%–5%,
and any decrease occurs along the steep portion of the dose-
response curve, allowing a graded response to hypoxia. Anal-
yses of cultured human cells have revealed that expression of
hundreds of genes was increased in response to hypoxia in
a HIF-1-dependent manner (as determined by RNA interference)
with direct binding of HIF-1 to the gene (as determined by
chromatin immunoprecipitation [ChIP] assays). In addition, the
expression of hundreds of genes was decreased in response
to hypoxia in a HIF-1-dependent manner, but binding of HIF-1
to these genes was not detected (Mole et al., 2009). These
results indicate that HIF-dependent repression occurs via
indirect mechanisms, which include HIF-1-dependent expres-
sion of transcriptional repressors (Yun et al., 2002) and
microRNAs (Kulshreshtha et al., 2007). ChIP-seq studies have
revealed that only 40% of HIF-1-binding sites are located within
2.5 kb of the transcription start site (Scho¨del et al., 2011).
In vertebrates, HIF-2a is a paralog of HIF-1a that is also
regulated by prolyl and asparaginyl hydroxylation. HIF-2a also
dimerizes with HIF-1b, but it is expressed in a cell-restricted
manner and plays important roles in erythropoiesis, vasculariza-
tion, and pulmonary development. In D. melanogaster, the gene
encoding the HIF-1a ortholog is designated similar, and its
paralog is designated trachealess because inactivating muta-
tions result in defective development of the tracheal tubes
(Wilk et al., 1996). In contrast, C. elegans has only a single
HIF-1a homolog (Epstein et al., 2001). Thus, in both invertebrates400 Cell 148, February 3, 2012 ª2012 Elsevier Inc.and vertebrates, the evolution of specialized systems for O2
delivery was associated with the appearance of a HIF-1a
paralog.
O2 and Metabolism
The regulation of metabolism is a principal and primordial
function of HIF-1. Under hypoxic conditions, HIF-1 mediates
a transition from oxidative to glycolytic metabolism through its
regulation of four factors: PDK1, LDHA, BNIP3, and BNIP3L.
PDK1 encodes pyruvate dehydrogenase (PDH) kinase 1, which
phosphorylates and inactivates PDH, thereby inhibiting the
conversion of pyruvate to acetyl coenzyme A for entry into the
tricarboxylic acid cycle (Kim et al., 2006; Papandreou et al.,
2006). LDHA encodes lactate dehydrogenase A, which converts
pyruvate to lactate (Semenza et al., 1996). Finally, BNIP3 (Zhang
et al., 2008) and BNIP3L (Bellot et al., 2009) mediate selective
mitochondrial autophagy (Figure 1). HIF-1 also mediates a
subunit switch in cytochrome c oxidase that improves the
efficiency of electron transfer under hypoxic conditions (Fukuda
et al., 2007). An analogous subunit switch is also observed
in Saccharomyces cerevisiae, although it is mediated by a
completely different mechanism (yeast lack HIF-1). This con-
servation suggests that the subunit switch in cytochrome c
oxidase may represent a fundamental response of eukaryotic
cells to hypoxia.
It is conventional wisdom that cells switch to glycolysis for
ATP production when O2 becomes limiting. Yet, HIF-1a null
mouse embryo fibroblasts, which do not downregulate respira-
tion under hypoxic conditions, have higher ATP levels at 1%
O2 than wild-type cells at 20% O2, demonstrating that under
these conditions O2 is not limiting for ATP production (Zhang
et al., 2008). However, the HIF-1a null cells die under prolonged
hypoxic conditions due to ROS toxicity (Kim et al., 2006; Zhang
et al., 2008). These studies have led to a paradigm shift with
regard to our understanding of the regulation of cellular metabo-
lism (Semenza, 2010): the purpose of switching to glycolysis
is to prevent excess mitochondrial generation of ROS that
would otherwise occur due to the reduced efficiency of electron
transfer under hypoxic conditions (Chandel et al., 1998). This
may be particularly important in stem cells, in which avoidance
of DNA damage is critical (Suda et al., 2011).
Role of HIFs in Development
Much of mammalian embryogenesis occurs at O2 concentra-
tions of 1%–5%, and O2 functions as a morphogen (through
HIFs) in many developmental systems (Dunwoodie, 2009).
Mice that are homozygous for a null allele at the locus encoding
HIF-1a die by embryonic day 10.5 with cardiac malformations,
vascular defects, and impaired erythropoiesis. Thus, all three
components of the circulatory system are dependent upon
HIF-1 for normal development (Iyer et al., 1998; Yoon et al.,
2011). Depending on the genetic background, mice lacking
HIF-2a die by embryonic day 12.5 with vascular defects (Peng
et al., 2000) or bradycardia due to deficient catecholamine
production (Tian et al., 1998); die as neonates due to impaired
lungmaturation (Compernolle et al., 2002); or die several months
after birth due to ROS-mediated multiorgan failure (Scortegagna
et al., 2003). Thus, although vertebrate evolution was associated
with concomitant appearance of the circulatory system and
HIF-2a, both HIF-1 and HIF-2 have important roles in circulatory
system development. Conditional knockout of HIF-1a in specific
types of cells has demonstrated important roles in chondrogen-
esis (the production of cartilage) (Schipani et al., 2001), adipo-
genesis (Yun et al., 2002), B lymphocyte development (Kojima
et al., 2002), osteogenesis (Wang et al., 2007), hematopoiesis
(Takubo et al., 2010), T lymphocyte differentiation (Dang et al.,
2011), and innate immunity (Zinkernagel et al., 2007). Although
knockout mouse experiments point to the adverse effects of
HIF-1 loss of function on development, it is also possible that
increased HIF-1 activity, induced by hypoxia in embryonic
tissues as a result of abnormalities in placental blood flow,
may also dysregulate development and result in congenital
malformations. For example, HIF-1a has been shown to interact
with and stimulate the transcriptional activity of Notch, which
plays a key role in many developmental pathways (Gustafsson
et al., 2005).
Diseases inwhich HIF-1Mediates Protective Responses
Coronary Artery Disease
Heart disease is the major cause of mortality in the United States
population. The formation of atherosclerotic plaques in the main
coronary arteries leads to insufficient myocardial perfusion,
especially when heart work and O2 consumption are increased.
A physiological response to myocardial ischemia (inadequate
perfusion of the heart muscle) is the remodeling of collateral
blood vessels to accept increased flow and thereby bypass
stenotic regions, where lumenal diameter and blood flow are
reduced. Two-thirds of patients with critical narrowing of a
coronary artery (>70% reduction in diameter) have one or more
collateral vessels. When rupture of atherosclerotic plaques
results in complete coronary occlusion andmyocardial infarction
(MI; ‘‘heart attack’’), patients with collaterals are likely to have
smaller infarcts (areas of tissue necrosis) and are more likely to
survive. In patients with critical coronary stenosis, the frequency
of a single-nucleotide polymorphism (SNP) that changes
proline to serine at residue 582 of HIF-1a was 5-fold greater
among those without collaterals compared to those with collat-
erals (Resar et al., 2005). This SNP and two others at the
HIF1A locus were associated with stable exertional angina
(chest pain during exercise) rather than MI as the initial clinical
presentation in patients with coronary artery disease (CAD)
(Hlatky et al., 2007). Coronary stenosis and collaterals were not
analyzed in this latter study, making interpretation of the data
difficult. However, taken together these two clinical studies
suggest that HIF1A is a major genetic modifier in CAD.
The remodeling of collateral vessels provides a means to
increase O2 delivery and thereby eliminate hypoxia. However,
in the short-term, cells must adapt to survive O2 deprivation,
such as by shifting from oxidative to glycolytic metabolism.
The powerful nature of these adaptations is illustrated by the
preconditioning phenomenon, in which exposure of the heart
to short periods (e.g., 5min [I5]) of ischemia, caused by occlusion
of a coronary artery, followed by short periods (e.g., 5 min [R5])
of reperfusion (recovery of blood flow) protect the heart against
subsequent episodes of prolonged ischemia (e.g., 30 min [I30]).
Hearts from Hif1a+/ mice (heterozygous for a null allele at theHif1a locus) show a complete loss of preconditioning (Cai
et al., 2008). In addition to its effects on glucose metabolism,
HIF-1 activates genes encoding enzymes that generate adeno-
sine, a signaling molecule that mediates preconditioning (Eckle
et al., 2008). The cardiac protection afforded by a precondition-
ing protocol lasting less than 1 hr (I5-R5-I5-R5-I30) is dependent
on HIF-1, indicating that HIF-1-dependent transcription and
subsequent translation occur with remarkable rapidity.
Peripheral Arterial Disease
Atherosclerotic stenosis of major arteries in the legs results in
ischemia that is manifested by intermittent claudication (leg
pain during walking). This can progress to critical limb ischemia
in which blood flow is not sufficient to maintain tissue viability,
resulting in pain at rest and gangrene (tissue necrosis) that even-
tually necessitates limb amputation. The incidence of peripheral
arterial disease (PAD) in the general population is5%, whereas
20% of individuals over 70 years old have PAD, and 1%–2% of
PAD patients develop critical limb ischemia. Limb ischemia
induced in experimental animals by ligation of the femoral artery
results in increased HIF-1a protein levels and HIF-1-dependent
expression of downstream target genes, encoding multiple
angiogenic growth factors. These factors include vascular
endothelial growth factor (VEGF), stromal-derived factor 1
(SDF-1), placental growth factor, angiopoietin 1, angiopoietin
2, platelet-derived growth factor B, and stem cell factor. In
addition, bone marrow-derived angiogenic cells (BMDACs) are
recruited to the ischemic tissue and, together with the local
effects of angiogenic factors, promote the recovery of tissue
perfusion. All of these responses to limb ischemia are impaired
in older mice and in Hif1a+/ mice (Bosch-Marce et al., 2007).
Clinical trials that target a single angiogenic factor (e.g., VEGF)
have failed to promote recovery of patients with PAD. The
observation that HIF-1 is amaster regulator, which is responsible
for the coordinated induction of multiple angiogenic factors,
suggested that it may represent a better therapeutic target
than a single angiogenic factor. AdCA5 is a recombinant adeno-
virus encoding an engineered formof HIF-1a that is constitutively
active. A single intramuscular injection of AdCA5 into the
ischemic limb was sufficient to overcome the impaired recovery
of blood flow following femoral artery ligation in 8-month-old
mice, but it was not effective in 13-month-old mice (Bosch-
Marce et al., 2007; Rey et al., 2009). Small hairpin RNA (shRNA)
targeting PHD2 or PHD3 also increased ischemic vascularization
in 3-month-old mice (Loinard et al., 2009). Thirteen-month-old
mice were rescued by a two-stage therapy, consisting of
intramuscular administration of AdCA5 followed 24 hr later by
intravenous administration of BMDACs, which were cultured
for 4 days in the presence of angiogenic growth factors and
DMOG.
The rationale for this staged approach with local and systemic
delivery was as follows. First, AdCA5 induces production of
angiogenic factors and thus provides a homing signal for
BMDACs. Second, direct injection of a large number of cells
into the ischemic tissue would increase cell death due to
hypoxia, whereas systemic administration would select for the
subpopulation of cells that were capable of homing to the
ischemic tissue to participate in the vascular remodeling
process. Combined therapy was ineffective if the BMDACsCell 148, February 3, 2012 ª2012 Elsevier Inc. 401
were not treated with DMOG. At themolecular level, activation of
HIF-1 in BMDACs had two important consequences. First, HIF-1
induced expression of b2 integrins, which mediate increased
adherence of circulating BMDACs to vascular endothelial cells,
thereby increasing BMDAC retention within ischemic tissue
(Rey et al., 2009). Second, metabolic reprogramming mediated
by HIF-1 increased BMDAC survival within ischemic tissue
(Rey et al., 2011). Combined therapy resulted in limb salvage
even when both BMDAC donor and ischemic recipient mice
were 17 months old, representing a model for autologous
BMDAC therapy for elderly patients with critical limb ischemia.
A recombinant adenovirus, which encoded the HIF-1a
bHLH-PAS domain fused to the herpes simplex virus VP16
transactivator protein, was administered to patients with critical
limb ischemia by intramuscular injection without any adverse
effects. However, the treatment had no significant therapeutic
effect in a phase II trial (Creager et al., 2011). Although this trial
involved administration of a potentially immunogenic non-native
protein, which may have contributed to failure, the results also
suggest that combined gene and cell therapy may be required
in humans, as well as in mice.
Wound Healing
The principal vascular response to heart or limb ischemia
involves arteriogenesis, the remodeling of collateral blood
vessels. In contrast, cutaneous wound healing requires angio-
genesis, the budding of new capillaries from existing vessels,
and vasculogenesis, in which nonresident cells are recruited to
participate in de novo blood vessel formation. Both local and
systemic responses to wounding contribute to the reparative
vascularization process. Endothelial cells in pre-existing vessels
are activated to initiate angiogenesis in the injured tissue. In
addition, the HIF-1-dependent release of cytokines from the
wound elicits the mobilization and homing of BMDACs, which
can participate in vasculogenesis or stimulate angiogenesis
through paracrine mechanisms.
As in the case of CAD and PAD, impaired wound healing is
associated with both aging and diabetes, with the combination
having synergistic negative effects (Brem et al., 2007). Foot
ulcers precede 85% of lower limb amputations in diabetic
individuals. HIF-1a expression was markedly decreased in
excisional skin wounds of young db/db mice when compared
to nondiabetic littermates (Mace et al., 2007). HIF-1 activity
was inhibited in skin fibroblasts from db/db mice exposed to
high glucose concentrations, which could be reversed by
treatment with DMOG or desferrioxamine. Topical application
of desferrioxamine also improved wound vascularization and
healing in db/db mice (Botusan et al., 2008; Thangarajah et al.,
2009). Aging was associated with decreased expression of
angiogenic factors and delayed wound healing in db/db mice
(Liu et al., 2008). Expression of CA5 (Liu et al., 2008) or other
constitutively active forms of HIF-1a (Mace et al., 2007; Botusan
et al., 2008) resulted in increased angiogenic gene expression,
BMDAC mobilization, wound vascularization, and an increased
rate of wound healing. Intramuscular administration of AdCA5
also improved recovery of perfusion and limb salvage after
femoral artery ligation in db/db mice (Sarkar et al., 2009).
Burn injuries represent a major health problem affecting
1 million Americans annually. In wild-type mice subjected to402 Cell 148, February 3, 2012 ª2012 Elsevier Inc.burn wounding, HIF-1a protein levels in the wound, SDF-1 levels
in plasma, and BMDACs circulating in blood were increased on
day 2, leading to increased wound vascularization and perfusion
on day 7. In Hif1a+/ mice, these angiogenic responses were
impaired (Zhang et al., 2010). Aging also impaired HIF-1a and
SDF-1 expression in response to burn wounding. When
BMDACs from young donor mice were injected intravenously,
homing to burn wound tissue was impaired in older recipients,
whereas the age of the BMDAC donor had no effect on homing
(Zhang et al., 2011b). In contrast, conditional knockout of
HIF-1a in Tie2 lineage cells (which include BMDACs and endo-
thelial cells) of either the donor or recipient inhibited BMDAC
homing to burn wounds (Sarkar et al., 2012).
Organ Transplant Rejection
Chronic rejection following lung transplantation, which is mani-
fested as obliterative bronchiolitis (airway fibrosis), accounts
for the 50% 5 year survival of recipients, which is the worst of
all organ allografts. The lung, which is perfused by the pulmonary
arteries, pulmonary veins, and bronchial artery, is the only organ
for which the major arterial blood supply is not re-established
during transplant surgery (Wilkes, 2011). Autopsy data indicate
that obliterative bronchiolitis is preceded by the loss of airway
microvasculature (Luckraz et al., 2004). In an orthotopic tracheal
transplantation model, analysis of knockout mice demonstrated
that HIF-1-dependent recruitment of recipient Tie2+ angiogenic
cells and repair of airway microvasculature were critical determi-
nants of graft survival. Furthermore, treatment of grafts with
AdCA5 prior to transplantation increased graft perfusion,
decreased fibrosis, and increased graft survival (Jiang et al.,
2011). These results represent a paradigm shift in our under-
standing of chronic rejection from a purely immunological
disease to one in which vascular responses to ischemia play
a major role. Chronic rejection of renal transplants also involves
destruction of the microvasculature, and in an allogenic kidney
transplant model, treatment of donor rats with a prolyl hy-
droxylase inhibitor prior to nephrectomy improved survival of
recipients (Bernhardt et al., 2009). Two major classes of
immunosuppressive drugs, calcineurin and mTOR inhibitors,
have been shown to block HIF-1 activity (Laughner et al., 2001;
Liu et al., 2007) in cultured cells. Therefore, these drugs may
exert unintended countertherapeutic effects. Finally, the poten-
tial role of aging-related impairment of HIF-1 activity in chronic
rejection of solid organ transplants warrants investigation.
Colitis
The pathogenesis of chronic gastrointestinal inflammatory
conditions such as Crohn’s disease and ulcerative colitis
includes microvascular abnormalities and tissue hypoxia. The
severity of colitis induced by chemical (Karhausen et al., 2004)
or bacterial (Hirota et al., 2010) toxins was increased in condi-
tional knockout mice lacking HIF-1a expression in intestinal
epithelial cells. Treatment of wild-typemice with DMOG reduced
the severity of chemical (Cummins et al., 2008) or bacterial
(Hirota et al., 2010) toxin-induced colitis.
Translational Prospects
Drug discovery programs have been initiated at many pharma-
ceutical and biotech companies to develop prolyl hydroxylase
inhibitors (PHIs) that, as described above for DMOG, induce
HIF activity for treatment of disorders in which HIF mediates
Table 1. Drugs that Inhibit HIF-1
Process Inhibited Drug Class Prototype
HIF-1a
protein
synthesis
cardiac glycoside
mTOR inhibitor
microtubule-targeting agent
topoisomerase I inhibitor
digoxin
rapamycin
2-methoxyestradiol
topotecan
HIF-1a
protein
stability
HDAC inhibitor
HSP90 inhibitor
calcineurin inhibitor
guanylate cyclase activator
LAQ824
17-AAG
cyclosporine
YC-1
Heterodimerization antimicrobial agent acriflavine
DNA binding anthracycline
quinoxaline antibiotic
doxorubicin
echinomycin
Transactivation proteasome inhibitor
antifungal agent
bortezomib
amphotericin B
Signal
transduction
BCR-ABL inhibitor
cyclooxygenase inhibitor
EGFR inhibitor
HER2 inhibitor
imatinib
ibuprofen
erlotinib, gefitinib
trastuzumabprotective physiological responses. Local and short-term induc-
tion of HIF activity by PHIs, gene therapy, or other means are
likely to be useful therapies for many of the diseases described
above. In the case of ischemic cardiovascular disease, local
therapy is needed to provide homing signals for the recruitment
of BMDACs. Chronic systemic use of PHIs must be approached
with great caution because individuals with genetic mutations
that constitutively activate the HIF pathway (discussed below)
have increased cardiovascular disease and mortality (Yoon
et al., 2011). On the other hand, the profound inhibition of HIF
activity and vascular responses to ischemia that are associated
with aging suggest that systemic replacement therapy might be
contemplated as a preventive measure for subjects for whom
impaired HIF responses to hypoxia can be documented.
In C. elegans, VHL loss of function increases life span in a
HIF-1-dependent manner (Mehta et al., 2009), providing further
evidence for a mutually antagonistic relationship between
HIF-1 and aging.
Diabetes is an even more complicated condition. Impaired
large-vessel responses to ischemia (CAD and PAD) and impaired
small-vessel responses to cutaneous wounding are both
common and due, at least in part, to loss of HIF activation.
However, diabetes is also associated with excessive small-
vessel proliferation (i.e., ocular neovascularization), and HIF-1
appears to play a key role in the pathogenesis of this complica-
tion (Yoshida et al., 2010).
Diseases in which HIF Activity Contributes
to Pathogenesis
Hereditary Erythrocytosis
Individuals with excess red blood cell production due to germline
mutations in the genes encoding VHL, PHD2, and HIF-2a have
been identified, demonstrating the essential role of this pathway
in regulating erythropoiesis (Yoon et al., 2011). These mutations
impair hydroxylation and ubiquitination, thereby increasing the
levels of HIF-1a and HIF-2a at any given partial pressure of O2
(PO2). Affected individuals manifest global physiologic changes
that include altered ventilatory and pulmonary vascular
responses to hypoxia (Smith et al., 2006) as well as altered
metabolic responses to exercise (Formenti et al., 2010).
Cancer
Cancers contain hypoxic regions due to high rates of cell
proliferation coupled with the formation of vasculature that is
structurally and functionally abnormal. Increased HIF-1a or
HIF-2a levels in diagnostic tumor biopsies are associated with
increased risk of mortality in cancers of the bladder, brain,
breast, colon, cervix, endometrium, head/neck, lung, ovary,
pancreas, prostate, rectum, and stomach. Experimental manip-
ulations that increase HIF-1a expression result in increased
tumor growth, whereas loss of HIF activity results in decreased
tumor growth (Semenza, 2010). HIFs are also activated by
genetic alterations in human cancers, most notably VHL loss of
function in clear cell renal carcinoma (Majmundar et al., 2010).
HIFs activate transcription of genes that play key roles in critical
aspects of cancer biology, including stem cell maintenance
(Wang et al., 2011), cell immortalization, epithelial-mesenchymal
transition (Mak et al., 2010), genetic instability (Huang et al.,
2007), vascularization (Liao and Johnson, 2007), glucose metab-olism (Luo et al., 2011), pH regulation (Swietach et al., 2007),
immune evasion (Lukashev et al., 2007), invasion andmetastasis
(Chan andGiaccia, 2007), and radiation resistance (Moeller et al.,
2007). Given the extensive validation of HIF-1 as a potential
therapeutic target, drugs that inhibit HIF-1 have been identified
and shown to have anticancer effects in xenograft models
(Table 1) (Semenza, 2010).
More than 100 women die every day of breast cancer in the
US. The mean PO2 is 10 mm Hg in breast cancer as compared
to >60 mm Hg in normal breast tissue, and cancers with PO2 <
10 mm Hg are associated with increased risk of metastasis
and patient mortality (Vaupel et al., 2004). Increased HIF-1a
protein levels, as identified by immunohistochemical analysis
of tumor biopsies, are associated with increased risk of metas-
tasis and patient mortality in unselected breast cancer patients
and in lymph node-positive, lymph node-negative, HER2+, or
estrogen receptor+ subpopulations (Semenza, 2010).Metastasis
is responsible for >90% of breast cancer mortality. The require-
ment for HIF-1 in breast cancer metastasis has been demon-
strated for both autochthonous (spontaneously arising) tumors
in transgenic mice (Liao et al., 2007) and orthotopic transplants
(injection of human breast cancer cells into the mammary fat
pad) in immunodeficient mice (Zhang et al., 2011a; Wong
et al., 2011). Primary tumors direct the recruitment of bone
marrow-derived cells to the lungs and other sites of metastasis
(Kaplan et al., 2005). In breast cancer, hypoxia induces the
expression of lysyl oxidase (LOX), a secreted protein that
remodels collagen at sites of metastatic niche formation (Erler
et al., 2009). In addition to LOX, breast cancers also express
LOX-like proteins 2 and 4. LOX, LOXL2, and LOXL4 are all
HIF-1-regulated genes. HIF-1 inhibition blocks metastatic niche
formation, regardless of which LOX/LOXL protein is expressed,
but available LOX inhibitors are not effective against all LOXL
proteins (Wong et al., 2011). These results again illustrate the
role of HIF-1 as a master regulator that controls the expression
of multiple genes involved in a single (patho)physiological
process.Cell 148, February 3, 2012 ª2012 Elsevier Inc. 403
Table 2. HIF Target Genes Expressed in Pulmonary Arterial
Smooth Muscle Cells in Pulmonary Hypertension
Target Gene(s) Protein Product(s) Consequence
EDN1 endothelin contraction
KCNA5, KCNB1 voltage-gated K+ channels increased [K+]i
TRPC1, TRPC6 transient receptor potential
Ca2+ channels
increased [Ca2+]i
NHE1 sodium-hydrogen exchanger increased pHi
PDK1 pyruvate dehydrogenase
kinase
glycolysisTraumatic Shock
Secondary lung injury is a major cause of death following severe
abdominal trauma. Wild-type mice subjected to abdominal
trauma/hemorrhagic shock develop intestinal villous necrosis
and a severe pulmonary inflammatory response, whereas both
gut and lung injury were attenuated in Hif1a+/ littermates
(Feinman et al., 2010). Delineation of the mechanisms underlying
maladaptive HIF-1-mediated responses to trauma, which are in
contrast to the protective role of HIF-1 in the experimental colitis
models described above, may identify novel therapeutic targets.
Pulmonary Arterial Hypertension
Prolonged exposure to alveolar hypoxia, which occurs in individ-
uals with chronic lung disease, results in a remodeling of the
pulmonary vasculature, leading to increased pulmonary arterial
pressure and right ventricular hypertrophy. Multiple HIF-1 target
genes that play key roles in the response of pulmonary artery
smooth muscle cells to hypoxia have been identified (Table 2)
(Shimoda and Semenza, 2011). Hif1a+/ and Hif2a+/ mice are
both protected from hypoxic pulmonary hypertension, indicating
that HIF-1a and HIF-2a play key pathogenic roles (Yu et al.,
1999; Brusselmans et al., 2003). HIFs are also implicated in
chemically induced and genetic forms of pulmonary arterial
hypertension in which hypoxia is not an inciting factor (Bonnet
et al., 2006).
Obstructive Sleep Apnea
In individuals with obstructive sleep apnea, pharyngeal soft
tissue occludes the airway, resulting in decreased partial pres-
sure of oxygen in the blood. This hypoxemia is sensed by carotid
body (CB) chemoreceptors, leading to arousal, clearing of
the airway, and reoxygenation. The cycle of hypoxia and reoxy-
genation is repeated dozens of times per night and results in
increased ROS levels in the CB and brain. Sympathetic activa-
tion and increased plasma catecholamine levels lead to systemic
hypertension. Obstructive sleep apnea is associated with both
hypoxia and hypercarbia (abnormally high levels of carbon
dioxide in the blood), but exposure of rodents to chronic intermit-
tent hypoxia (CIH) is sufficient to elicit hypertension (Fletcher
et al., 1992). Treatment of mice with the superoxide scavenger
MnTMPyP blocks CIH-induced increases in HIF-1a, catechol-
amines, and blood pressure, indicating that HIF-1 is downstream
of ROS. However, Hif1a+/ mice lack CIH-induced increases in
ROS, catecholamines, and blood pressure, suggesting that
HIF-1 is upstream of ROS (Peng et al., 2006). Recent data
support the existence of a feedforward loop in which ROS
trigger HIF-1a induction, leading to transcription of the Nox2404 Cell 148, February 3, 2012 ª2012 Elsevier Inc.gene encoding NADPH oxidase, which generates superoxide
radicals (Yuan et al., 2011).
HIF-1a is expressed at low levels in the CB under normoxic
conditions (normal PO2) and is induced by CIH. In contrast,
HIF-2a expression is high in the CB under normoxic conditions
and decreased due to calpain-dependent degradation in
response to CIH (Nanduri et al., 2009). Decreased HIF-2a levels
are associated with decreased expression of the Sod2 gene,
which encodes the mitochondrial superoxide dismutase that
converts superoxide to hydrogen peroxide. Treatment of CIH-
exposed rats with a calpain inhibitor blocks HIF-2a degradation,
restores SOD2 activity, and prevents oxidative stress and
hypertension. Thus, disruption of the balance between HIF-1a
and HIF-2a levels in the CB is central to the pathogenesis of
CIH-induced hypertension. It is striking that continuous hypoxia
induces HIF-1a and HIF-2a, resulting in pulmonary hypertension
(Figure 2A), whereas CIH induces HIF-1a but inhibits HIF-2a,
resulting in systemic hypertension (Figure 2B).
When isolated CBs from wild-type mice are superfused with a
hypoxic gas mixture, increased depolarization of the O2-sensing
glomus cells and carotid sinus nerve activity are elicited,
but these responses are absent in CBs from Hif1a+/ mice
(Peng et al., 2006). In contrast, CBs from Hif2a+/ mice have
augmented responses to acute hypoxia, and the mice manifest
increased catecholamines and blood pressure under normoxic
conditions (Peng et al., 2011). MnTMPyP treatment of Hif2a+/
mice normalizes blood pressure and CB responses. Thus,
even under normoxic conditions, the balance between HIF-1a
and HIF-2a controls CB function and cardiovascular homeo-
stasis. Functional antagonism has also been reported in the
regulation of nitric oxide (Takeda et al., 2010) and VEGF (Eubank
et al., 2011) signaling by macrophages. These findings provide
new insight into the logic underlying the acquisition of a HIF-1a
paralog during vertebrate evolution.
Translational Prospects
Small-molecule inhibitors of HIF activity that have anticancer
effects in mousemodels have been identified (Table 1). Inhibition
of HIF impairs both vascular and metabolic adaptations to
hypoxia, which may decrease O2 delivery and increase O2 utili-
zation. These drugs are likely to be useful (as components of
multidrug regimens) in the treatment of a subset of cancer
patients for whom high HIF activity is driving progression. As
with all new cancer therapeutics, successful translation will
require the development of methods for identifying the appro-
priate patient cohort. Effects of combination drug therapy also
need to be considered. VEGF receptor tyrosine kinase inhibitors,
which induce tumor hypoxia by blocking vascularization, have
been reported to increase metastasis in mouse models (Ebos
et al., 2009), which may be mediated by HIF-1. If so, combined
use of HIF-1 inhibitors with these drugs may prevent unintended
countertherapeutic effects.
HIF inhibitors may also be useful in the treatment of other
diseases in which dysregulated HIF activity is pathogenic. Proof
of principle has been established in mouse models of ocular
neovascularization, a major cause of blindness in the developed
world, inwhich systemicor intraocular injection of theHIF-1 inhib-
itor digoxin blocks excess blood vessel formation (Yoshida et al.,
2010).SystemicadministrationofHIF inhibitors forcancer therapy
Figure 2. Vascular Effects of Continuous and Intermittent Hypoxia
(A) Chronic continuous alveolar hypoxia results in pulmonary arterial hyper-
tension (increased blood pressure in the pulmonary artery). Activation of both
HIF-1a and HIF-2a leads to changes in pulmonary arterioles that reduce
lumenal diameter, thereby increasing pulmonary vascular resistance.
(B) Chronic intermittent hypoxia results in systemic arterial hypertension due to
activation of HIF-1a and degradation of HIF-2a. Increased HIF-1a-dependent
expression of NADPH oxidase 2 (NOX2), which generates superoxide anion,
and decreased HIF-2a-dependent expression of superoxide dismutase
2 (SOD2), which consumes superoxide, result in increased ROS levels in
the carotid body, leading to sympathetic nervous system activation and
systemic hypertension.would be contraindicated in patients who also have ischemic
cardiovascular disease, in which HIF activity is protective.
O2 and Evolution, Part 2
When lowlanders sojourn to high altitude, hypobaric hypoxia
induces erythropoiesis. This is a relatively ineffective response
because the problem is not insufficient red cells but rather insuf-
ficient ambient O2. Chronic erythrocytosis increases the risk of
heart attack, stroke, and fetal loss during pregnancy. Many
high-altitude Tibetans maintain the same hemoglobin concen-
tration as lowlanders, and yet, despite severe hypoxemia, they
also maintain aerobic metabolism. The basis for this remarkable
evolutionary adaptation appears to have involved the selectionof genetic variants at multiple loci encoding components of
the oxygen-sensing system, particularly HIF-2a (Beall et al.,
2010; Simonson et al., 2010; Yi et al., 2010). Given that heredi-
tary erythrocytosis is associated with modest HIF-2a gain of
function, the Tibetan genotype associated with absence of an
erythrocytotic response to hypoxia may encode reduced HIF-
2a activity along with other alterations that increase metabolic
efficiency. Delineating the molecular mechanisms underlying
these metabolic adaptations may lead to novel therapies
for ischemic disorders, illustrating the importance of oxygen
homeostasis as a nexus where evolution, biology, and medicine
converge.
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